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Background: In vitro fertilization is an important therapy for women with polycystic 
ovarian syndrome (PCOS). The use of new ways of improving clinical results is yet
required.
Objective: This study was aimed to investigate the efficacy of progesterone primed 
ovarian stimulation (PPOS) and compare with conventional antagonist protocol in
PCOS.
Materials and Methods: A total of 120 PCOS women who were candidates for assisted 
reproductive technology treatment from May  2018 to January 2019 were enrolled in
this  RCT and were placed into two groups, randomly (n = 60/each). The PPOS
group  received 20 mg/day Dydrogesterone orally since the second day of the  cycle
and the  control group received antagonist protocol. The pregnancy outcomes
including the  chemical and clinical pregnancy, the miscarriage rate, and the percent
of gestational sacs/transferred embryos was compared in two groups.
Results: Number of MII oocyte, maturity rate, Number of 2 pronuclei (2PN) and serum 
estradiol levels on trigger day were statistically lower in PPOS group (p = 0.019, p =
0.035, p = 0.032, p = 0.030), respectively. Serum LH level on trigger day in PPOS 
group was higher than antagonist group (p = 0.005). Although there wasn’t sever 
ovarian hyper simulation syndrome in any participants, mild and moderate ovarian 
hyper simulation syndrome was less in PPOS group (p = 0.001). Also, the chemical 
and clinical pregnancy rate were higher in the antagonist group, althoughit was not 
statistically significant (p = 0.136, p = 0.093 respectively).
Conclusion: Our study demonstrate that PPOS does not improve chemical and clinical 
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1. Introduction
Polycystic ovarian syndrome (PCOS) is a
prevalent endocrine disorder. About 6.3–21.4%
of women in the reproductive age suffers from
this disease. In vitro fertilization (IVF) is one of
the important therapy for women with PCOS.
Regardless of the higher number of retrieved
oocytes in PCOS patients, low fertility rate, poor
oocytes quality, and high rates of abortion are yet
an important issues. Therefore, new protocols are
needed to improve clinical outcomes (1). Nowadays
we are observing the “freeze-all” techniques that
freeze the entire number of oocytes or embryos,
which we could utilize ovarian stimulation with no
restriction, including adverse effects of hormones
on endometrial receptivity (2).
It has been proved that progesterone prevents
pulsatile secretion of luteinizing hormone (LH) and
gonadotropin releasing hormone (GnRH) (3).
In order to inhibit LH increasing,
progestin-primed ovarian stimulation (PPOS)
was stated. In this protocol oral progesterone (P)
injected from the initial day of ovarian stimulation
at the follicular phase (4). Using this novel PPOS
protocol, P level, are utilized as the substitutions of
GnRH analogue to inhibit the early LH surge during
the follicular stage (5).
The effects of progestin and the freeze-all
strategy suggests that progestin-primed can be
used as an ideal regimen for PCOS patients who
are treated with assisted reproductive technology
(ART) (6). In addition, progestin administrated orally
and it is more convenient.
Freeze all embryos strategy and transfer in a
subsequent cycle, can reduce the late onset ovarian
hyper simulation syndrome (OHSS).
To avoid hypothalamic pituitary ovarian hypoxia,
gonadotropin releasing hormone agonist (GnRHa)
with a low dose of hCG (1000IU) as the final
triggering was used with low risk of moderate or
severe OHSS. Selecting the appropriate progestin
is essential for the PPOS protocol success (5).
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  Dydrogesterone (duphaston) is an artificial 
progesterone and is highly similar to endogenous 
progesterone in terms of its pharmacologic 
properties and molecular structure. In addition, it 
does not interfere with endogenous progesterone 
production (3). This drug is widely used to treat
hormone replacement, abortion, and the luteal 
support in pregnancy (5).
  In the present study, it was hypothesized that 
dydrogesterone could be utilized as a substitute 
progestin in a PPOS protocol. We designed a 
randomized clinical trial (RCT) to evaluate the 
cycle characteristics and pregnancy outcome of 
individuals with PPOS and compare them with 
conventional antagonist.
2. Materials and Methods
2.1. Study design
  A total of 120 individuals with PCOS aged 
between 18–40 yr old and were candidate for ART 
treatment were enrolled in this study. The study was 
taken place in Yazd Research and Clinical Center for 
Infertility between May 2018 to January 2019.
  PCOS diagnosis was performed based on 
Rotterdam criteria (2003), including polycystic 
ovaries, oligo-anovulation, as well as the biochem-
ical or clinical signs of hyperandrogenism (7).
  Women with the history of intrauterine 
abnormalities (submucosal fibroma, uterine polyp,
and intrauterine adhesions), severe endometriosis,
systemic diseases, and azoospermia in their 
husbands were excluded from the study. Grouping 
was done by disclosing the sealed envelopes.
  All subjects received 150 subcutaneous doses 
of Cinnal-f (Cinnagen, Iran) from the 2nd day of
the cycle. Women in progesterone primed (PPOS)
group, were prescribed 20 mg oral dose of 
dydrogesterone (duphaston, Abbott, Netherlands)
from the 2nd day of the cycle and continued until 
triggering day. Vaginal sonography was done for all
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patients since 6th day of cycle. In the antagonist
group, when the size of dominant follicles reached
to 12–13 mm, 0.25 mg of cetrotide (Merck-Serono
Germany) was injected subcutaneously daily and
continued until triggering day.
When dominant follicles reached 17 mm,
serum LH, E2 and P were checked. Then the
final triggering was performed by Subcutaneous
injection of decapeptyl 0.2 mg (Ferring, Germany)
and intramuscular injection of human chorionic
gonadotropin (HCG) 1000 IU (Pregnyl-Germany) in
both groups. Oocytes pick up was done 36 hr later.
All embryos were frozen in cleavage stage and
frozen embryo transfer was done 2 months later.
2.2. Embryo vitrification and warming
Cryopreservation of all embryos was done by
cryotop vitrification method on 2nd or 3rd day after
oocyte retrieval in both groups (8).
2.3. Endometrium preparation
Endometrial preparation process were similar
in both groups. All subjects received 6 mg/day
estradiol valerate (Aburaihan Co., Tehran, Iran) orally
from the 2nd day of menstrual cycle.
Vaginal ultrasonography was performed to
measure endometrial thickness on the 13th
day of menstrual cycle. When endometrial
thickness reached ≥8 mm, all subjects received
400 mg of Cyclogest R©vaginal peccaries (Cox
Pharmaceuticals, Barnstaple, UK) twice a day until
menstruation or 8 wk of gestational age in pregnant
women. Embryo transfer was performed three days
after progesterone administration.ering,. Estradiol
and progesterone injection continued for up to 8 wk
after pregnancy.
2.4. Pregnancy outcomes
Chemical pregnancy was determined by serum
β hCG > 50 IU/L two wk after ET. In addition,
clinical pregnancy was confirmed by detecting fetal
heartbeats 2 wk following the positive β hCG.
The miscarriage was defined as losing pregnancy
prior to 20 wk of gestation. The implantation
rate was considered as percentage of gestational
sacs/transferred embryos.
2.5. Ethical consideration
The Ethics Committee of Yazd Reproductive
Sciences Institute approved the study protocol
(code: IR.SSU.RSI.REC.1397.003). The study was
registered at IRCT (Iranian Registry of Clinical Trials)
under code IRCT20110509006420N18 Written
informed consent was obtained from all subjects
after counseling about conventional antagonist
protocol and PPOS.
2.6. Statistical analysis
The statistical analysis was performed using
SPSS software (Statistical Package for the Social
Sciences, version 20.0, Chicago, IL, USA). In order
of identifying major differences in the two groups,
both chi-square and t-test were utilized. P < 0.05
was regarded as the significance level.
3. Results
A total of 120 women who met the inclusion
criteria enrolled the study as 2 groups (n =
60/each). Two patients failed to follow-up in the
study due to familial problems group (Figure 1). The
baseline characteristics were similar in both groups
(Table I).
There was no significant different between
duration of stimulation, total dose of gonadotropin
and No. of retrieved oocyte between two groups.
No. of MII oocyte, maturity rate, No. of 2 pronuclei
(2PN) and serum E2 levels on trigger day were lower
in PPOS group (p = 0.019, p = 0.035, p = 0.032,
p = 0.030 respectively).
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Serum LH level on trigger day in PPOS group
was higher than antagonist group (5.29 vs. 3.79;
p = 0.005). Although there wasn’t sever OHSS
in any patient, mild and moderate OHSS was
Table I. Basic characteristics of the participants in two groups
Variable PPOS group Antagonist group P-value
Female age (yr)∗ 28.47 ± 3.60 28.98 ± 3.55 0.433
Duration of infertility (yr)∗ 6.00 ± 2.84 6.88 ± 3.65 0.154
Type of infertility∗∗
Primary 48 (82.8) 46 (76.7) 0.411
Secondary 10 (17.2) 14 (23.3)
AMH (IU/L)∗ 8.95 ± 3.70 9.76 ± 4.64 0.302
∗Data presented as mean ± SD; Student’s t-test; ∗∗Data presented as n (%); Chi- square
AMH: Anti mullerian hormone; PPOS: Progesterone primed ovarian stimulation; Yr: Year
Table II. Results of ovarian stimulation
Variable PPOS group Antagonist group P-value
Duration of stimulation (day)∗ 10.24 ± 2.39 9.53 ± 2.01 0.084
Total dose of gonadotropin (IU)∗ 1528.45 ± 413.15 1430.00 ± 354.45 0.167
No. of retrieved oocytes∗ 15.74 ± 9.88 18.65 ± 7.87 0.083
No. of MII oocytes∗ 12.50 ± 8.88 16.03 ± 6.99 0.019
Maturity rate∗∗∗ 79.90% 85.52% 0.035
No. of two pronucleus∗ 8.70 ± 7.43 11.38 ± 5.68 0.032
No. of obtained embryos∗ 7.91 ± 6.63 9.48 ± 4.62 0.141
Total cycle cancelation∗∗ 4 (6.9%) 0 (0%) 0.038
E2 levels on trigger day (pg/mL)∗ 2351.55 ± 965.58 3047.68 ± 2157.04 0.030
LH levels of on trigger (IU/mL)∗ 5.29 ± 3.79 3.56 ± 2.61 0.005
P levels on trigger day (IU/mL)∗ 0.72 ± 1.25 0.81 ± 0.92 0.687
Fertilization rate∗∗∗ 63.26% 71.30% 0.073
Endometrial thickness (mm)∗ 9.20 ± 1.34 8.83 ± 1.14 0.161
OHSS (mild and moderate)∗∗∗ 36.5% 68.3% 0.001
∗Data presented as mean ± SD; Student’s t-test; ∗∗Data presented as n (%); Chi- square; Data presented as percentages
PPOS: Progesterone primed ovarian stimulation; MII: Mature oocyte II; E2: Estradiol; LH: Luteinizing hormone; P level: Progesterone
level; OHSS: Ovarian hyper stimulation syndrome
Table III. ART outcomes in frozen embryo cycles
Variable PPOS group Antagonist group P-value#
Implantation rate∗ 7.32% 15.69% 0.062
Chemical pregnancy rate/transfer∗∗ 13 (31.7) 24 (47) 0.136
Clinical pregnancy rate/transfer∗∗ 6 (14.6) 15 (29.4) 0.093
Abortion rate∗∗ 8 (61.5) 9 (37.5) 0.161
#∗Data presented as (%); ∗∗Data presented as n (%)
Chi square PPOS: Progesterone primed ovarian stimulation
less in PPOS group (36.5% vs. 68.3%; p = 0.001)
(Table II). Chemical and clinical pregnancy were
more in antagonist group which was not statistically
significant (Table III).
Page 674 https://doi.org/10.18502/ijrm.v17i9.5103
International Journal of Reproductive BioMedicine Progesterone-primed ovarian stimulation
Enrollment
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Excluded (n = 0)
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Figure 1. Consort Flow Diagram.
4. Discussion
In this present study, clinical efficiency of
duphaston in PPOS regimen were evaluated. Our
results showed that duphaston as an FSH adjuvant
to during the ovarian stimulation did not lead to
similar mature oocyte retrieval. Oocyte maturity
was mainly utilized to assess the oocyte quality.
The maturity rate of oocytes in PPOS group
was significantly lower than antagonist group. In
addition, fertilization rate was lower in the PPOS
group.
The pregnancy results of FET in PPOS showed
a lower clinical pregnancy rate, 14.6% vs. 29.9%.
The implantation rate was also lower in PPOS
group, although it was not statistically significant but
clinically notable. Although duphaston increased
the early LH rate, it did not interfere with the
measurements of progesterone. However, in the
present study, the mean level of LH was significantly
higher in the PPOS group.
Previous studies has shown that when
progesterone is administered during the regular
follicular phase, it decreases the the LH pulse
frequency, increases the amplitude LH pulse, and
decreases the mean LH levels of plasma compared
with those who were not treated (3).
The LH level reached its highest value at the
mid-cycle time and causes the meiosis I reinitiate
inside pre-ovulatory follicles. The mentioned time
is crucial for successful fertilization, perfect embryo
development, and egg maturity. It seems that there
is a level of LH capacity which the overexposure
can affect the prohibition of ovulation by controlling
the granulosa distribution, oocyte atresia, early
luteinization and ultimately affects IVF outcome.
However, the appropriate level of LH on trigger day
was not determined (9).
In the present study, estradiol level on trigger
day was significantly lower in PPOS group.
The effect of over-physiological levels of E2
on IVF outcomes are still controversial. Some
researchers have stated that the serum E2
concentrations on the day of hCG administration
have a positive correlation with pregnancy
outcomes. Nevertheless, some other researchers
have reported adverse or no effects of high levels
of E2 association between the levels of E2 serum
and the IVF outcomes of (10–12). All studies that
investigated the effect of estradiol on pregnancy
were conducted under the fresh embryo transfer
conditions (10–12). In the literature review, there
was no study that made to determine the effect
of estradiol serum level in trigger day on frozen
embryo outcome. In the current study, the lower
level of estradiol on the trigger day was correlated
with the lower numbers of mature oocytes.
Kuang and colleagues conducted a primary
randomized study on PPOS. They added
medroxyprogesterone acetate to gonadotropin-
induced stimulation in the follicular phase, and
compared this protocol with traditional short
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protocol. They demonstrated that pregnancy,
implantation, and miscarriage rates were not
meaningfully different between groups (13).
In another study Nanako lwami and co-workers
compared the rates of ongoing and clinical
pregnancies between the antagonist regimen
and the PPOS protocol. They used oral
dydrogesterone and HMG in the PPOS protocol.
They concluded that the rates of ongoing and
clinical pregnancies were similar in both groups
which is in contrast with our results. However, they
included normal responders in addition to hyper-
responders (14).
In a pilot study, a short protocol was compared
with the PPOS protocol in PCOS patients. This
article reported no significant differences in the
number of collected oocyte and the incidence of
ongoing pregnancy. However, a high dose of HMG
was consumed in the PPOS group. Considering the
particular risk of OHSS, two cases were reported
in the short protocol group vs. none in the PPOS
group (p = 0.154) (6).
5. Conclusion
In conclusion, the results of the present study
showed that PPOS is not appropriate for women
with PCOS, however, the results of previous studies
on PPOS were in contrast with this present study. It
seems that further randomized clinical trials (RCTs)
are required for better assessment of PPOS in
PCOS.
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